Form POS AM Howard Bancorp Inc
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
HOWARD BANCORP, INC.
(Exact name of Registrant as specified in its charter)
Maryland | 20-3735949 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
3301 Boston Street
Baltimore, MD 21224
(410) 750-0020
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Vincent J. Delie, Jr.
Chairman, President and Chief Executive Officer
F.N.B. Corporation
One North Shore Center
12 Federal Street
Pittsburgh, Pennsylvania 15212
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Copy to:
Gary R. Walker, Esq.
Reed Smith LLP
Reed Smith Centre
225 Fifth Avenue
Pittsburgh, PA, 15222
Telephone: (412) 288-3131
Fax: (412) 288-3063
Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to this registration statement.
If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☒ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) ☐
Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) ☐
EXPLANATORY NOTE
DEREGISTRATION OF SECURITIES
This Post-Effective Amendment No. 1 relates to the Registration Statement on Form S-4, File No. 333-221450 (the Registration Statement), of Howard Bancorp, Inc. (the Registrant), which was originally filed with the Securities and Exchange Commission (the SEC) on November 9, 2017, and amended by Pre-Effective Amendment No. 1 to Form S-4 Registration Statement filed with the SEC on November 21, 2017, pertaining to the registration of 9,143,230 shares of the Registrants common stock, par value $0.01 per share (the Registrants Common Stock) in connection with a merger with First Mariner Bank.
Pursuant to the Agreement and Plan of Merger between F.N.B. Corporation (F.N.B.) and the Registrant, dated as of July 12, 2021 (the Merger Agreement), the Registrant merged with and into F.N.B., effective as of January 22, 2022, with F.N.B. being the surviving corporation (the Merger). As a result of completion of the Merger, each outstanding share of the Registrants Common Stock was converted into the right to receive 1.8 common shares of F.N.B., par value $0.01 per share (except certain shares of the Registrants Common Stock held by F.N.B., the Registrant and their respective subsidiaries, which were cancelled without receipt of the merger consideration), with cash paid in lieu of any fractional shares of F.N.B. common stock.
Due to completion of the Merger, the Registrant has terminated any offering of the Registrants securities pursuant to any registration statement. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration all of such securities of the Registrant registered but unsold under the Registration Statements, if any.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-4 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form S-4 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Pittsburgh, Commonwealth of Pennsylvania, on January 24, 2022.
F.N.B. CORPORATION (as successor by merger to Howard Bancorp, Inc.) | ||||
By: |
/s/ Vincent J. Delie, Jr. | |||
Name: Vincent J. Delie, Jr. | ||||
Title: Chairman, President and Chief Executive Officer |
No other person is required to sign this Post-Effective Amendment to the Registration Statement on Form S-4 in reliance on Rule 478 of the Securities Act of 1933, as amended.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. to Report First Quarter 2022 Financial Results on Thursday, June 9, 2022
- Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Corcept, and RBB and Encourages Investors to Contact the Firm
- Vibrant's Novel Drug-Free Treatment Demonstrates Positive Efficacy and Safety Results in Adults with Chronic Idiopathic Constipation in Pivotal Phase 3 Study
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!